Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 11, 2008, Pages 2137-2142

  Fujita, Ken Ichi ^a,b   Nagashima, Fumio ^a,b   Yamamoto, Wataru ^a   Endo, Hisashi ^a   Sunakawa, Yu ^a   Yamashita, Keishi ^a   Ishida, Hiroo ^a   Mizuno, Keiko ^a   Matsunaga, Mototsugu ^a   Araki, Kazuhiro ^a   Tanaka, Ryuhei ^a   Ichikawa, Wataru ^a   Miya, Toshimichi ^a   Narabayashi, Masaru ^a   Akiyama, Yuko ^a,b   Kawara, Kaori ^a   Ando, Yuichi ^a   Sasaki, Yasutsuna ^a,b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biliary excretion; Irinotecan; Multidrug resistance protein 2; SN 38; Systemic exposure

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABCC2 GENE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEMATOLOGIC DISEASE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENOTYPE; HAPLOTYPES; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LEUCOVORIN; LINKAGE DISEQUILIBRIUM; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 55549141199     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.2137     Document Type: Article

References (21)

1. Teufel A., Steinmann S., Siebler J., Zanke C., Hohl H., Adami B., Schroeder M., Klein O., Höhler T., Galle P. R., Heike M., Moehler M., BMC Cancer, 4, 38-45 (2004).
2. Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P., Lancet, 355, 1041-1047 (2000).
3. Iyer L., King C. D., Whitington P. F., Green M. D., Roy S. K., Tephly T. R., Coffman B. L., Ratain M. J., J. Clin. Invest., 101, 847-854 (1998).
4. Kawahara M., Expert Opin. Drug Saf., 5, 303-312 (2006).
5. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., Hasegawa Y., Cancer Res., 60, 6921-6926 (2000).
6. Innocenti F., Undevia S. D., Iyer L., Chen P. X., Das S., Kocherginsky M., Karrison T., Janisch L., Ramírez J., Rudin C. M., Vokes E. E., Ratain M. J., J. Clin. Oncol., 22, 1382-1388 (2004).
7. Sai K., Saeki M., Saito Y., Ozawa S., Katori N., Jinno H., Hasegawa R., Kaniwa N., Sawada J., Komamura K., Ueno K., Kamakura S., Kitakaze M., Kitamura Y., Kamatani N., Minami H., Ohtsu A., Shirao K., Yoshida T., Saijo N., Clin. Pharmacol. Ther., 75, 501-515 (2004).
8. Han J. Y., Lim H. S., Shin E. S., Yoo Y. K., Park Y. H., Lee J. E., Jang I. J., Lee D. H., Lee J. S., J. Clin. Oncol., 24, 2237-2244 (2006).
9. Minami H., Sai K., Saeki M., Saito Y., Ozawa S., Suzuki K., Kaniwa N., Sawada J., Hamaguchi T., Yamamoto N., Shirao K., Yamada Y., Ohmatsu H., Kubota K., Yoshida T., Ohtsu A., Saijo N., Pharmacogenet. Genomics, 17, 497-504 (2007).
10. Araki K., Fujita K., Ando Y., Nagashima F., Yamamoto W., Endo H., Miya T., Kodama K., Narabayashi M., Sasaki Y., Cancer Sci., 97, 1255-1259 (2006).
11. Chu X.-Y., Kato Y., Sugiyama Y., Cancer Res., 57, 1934-1938 (1997).
12. Sugiyama Y., Kato Y., Chu X.-Y., Cancer Chemother. Pharmacol., 42, S44-S49 (1998).
13. Suzuki H., Sugiyama Y., Adv. Drug Deliv. Rev., 54, 1311-1331 (2002).
14. Itoda M., Saito Y., Soyama A., Saeki M., Murayama N., Ishida S., Sai K., Nagano M., Suzuki H., Sugiyama Y., Ozawa S., Sawada Ji. J., Drug Metab. Dispos., 30, 363-364 (2002).
15. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K., Pharmacogenetics, 11, 175-184 (2001).
16. Fujita K., Ando Y., Nagashima F., Yamamoto W., Eodo H., Araki K., Kodama K., Miya T., Narabayashi M., Sasaki Y., Cancer Chemother. Pharmacol., 60, 515-522 (2007).
17. Toh S., Wada M., Uchiumi T., Inokuchi A., Makino Y., Horie Y., Adachi Y., Sakisaka S., Kuwano M., Am. J. Hum. Genet., 64, 739-746 (1999).
18. Choi J. H., Ahn B. M., Yi J., Lee Ji H., Lee Je. H., Nam S. W., Chon C. Y., Han K. H., Ahn S. H., Jang I. J., Cho J. Y., Suh Y., Cho M. O., Lee J. E., Kim K. H., Lee M. G., Pharmacogenet. Genomics, 17, 403-415 (2007).
19. Kroetz D. L., Liu W., Nguyen T. D., Zwecker B. M., Ramirez J., Innocenti F., Ratain M. J., J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I, 24, 13072 (2006).
20. de Jong F. A., Scott-Horton T. J., Kroetz D. L., McLeod H. L., Friberg L. E., Mathijssen R. H., Verweij J., Marsh S., Sparreboom A., Clin. Pharmacol. Ther., 81, 42-49 (2007).
21. Han J. Y., Lim H. S., Shin E. S., Yoo Y. K., Park Y. H., Lee J. E., Jang I. J., Lee D. H., Lee J. S., Cancer, 110, 138-147 (2007).